Senseion Therapeutics, Inc.
Saint Louis, MO · Biotech · Private
Small-molecule drugs targeting LRRC8 proteins for dual glycemic control and antiplatelet/antithrombotic activity in Type 2 diabetes and cardiovascular disease
- Grants
- $7.0M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $301,025 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $945,785 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes | $993,178 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes | $990,929 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $1,089,280 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $323,485 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting LRRC8 signaling to prevent and treat arterial thrombosis in type 2 diabetes | $323,485 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $982,162 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $1,015,058 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1322 | Morphic Therapeutic | — | — |
| 1323 | LEFLORE TECHNOLOGIES LLC | — | — |
| 1324 | NRG Therapeutics | — | — |
| 1325 | Senseion Therapeutics, Inc. | — | — |
| 1326 | Sequegenics LLC | — | — |
| 1327 | Nellone Therapeutics, Inc. | — | — |
| 1328 | Prox Capital Holdings, LLC | — | $800K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- The Use Of LRRC8 Protein Modulators To Prevent And Treat Cardiovascular Diseaseapplication
- Suppression Of Inflammasome Activationapplication
- SWELL1-LRRC8 Complex Modulatorsapplication
- Suppression Of Inflammasome Activationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.